KR20230116833A - Dr4 및/또는 dr5를 표적화하는 폴리펩티드 및 관련 조성물 및 방법 - Google Patents

Dr4 및/또는 dr5를 표적화하는 폴리펩티드 및 관련 조성물 및 방법 Download PDF

Info

Publication number
KR20230116833A
KR20230116833A KR1020237020902A KR20237020902A KR20230116833A KR 20230116833 A KR20230116833 A KR 20230116833A KR 1020237020902 A KR1020237020902 A KR 1020237020902A KR 20237020902 A KR20237020902 A KR 20237020902A KR 20230116833 A KR20230116833 A KR 20230116833A
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237020902A
Other languages
English (en)
Korean (ko)
Inventor
장-필리프 즬리앵
장-필리프 ?x리앵
디에스 에두르네 루하스
Original Assignee
더 호스피탈 포 식 칠드런
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 호스피탈 포 식 칠드런 filed Critical 더 호스피탈 포 식 칠드런
Publication of KR20230116833A publication Critical patent/KR20230116833A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237020902A 2020-11-25 2021-11-25 Dr4 및/또는 dr5를 표적화하는 폴리펩티드 및 관련 조성물 및 방법 Pending KR20230116833A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118306P 2020-11-25 2020-11-25
US63/118,306 2020-11-25
PCT/CA2021/051690 WO2022109743A1 (en) 2020-11-25 2021-11-25 Polypeptides targeting dr4 and/or dr5 and related compositions and methods

Publications (1)

Publication Number Publication Date
KR20230116833A true KR20230116833A (ko) 2023-08-04

Family

ID=81753696

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237020902A Pending KR20230116833A (ko) 2020-11-25 2021-11-25 Dr4 및/또는 dr5를 표적화하는 폴리펩티드 및 관련 조성물 및 방법

Country Status (9)

Country Link
US (1) US20240182544A1 (cg-RX-API-DMAC7.html)
EP (1) EP4251654A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023550191A (cg-RX-API-DMAC7.html)
KR (1) KR20230116833A (cg-RX-API-DMAC7.html)
CN (1) CN116917339A (cg-RX-API-DMAC7.html)
AU (1) AU2021386892A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202378A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006148A (cg-RX-API-DMAC7.html)
WO (1) WO2022109743A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024003139A (es) * 2021-09-13 2024-06-24 Hospital For Sick Children Multabody dirigido a dr5 para el tratamiento del cancer.
WO2024050648A1 (en) * 2022-09-11 2024-03-14 Radiant Biotherapeutics Inc. Treatment of chemo-resistant tumors using multabodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391162B (es) * 2015-10-30 2025-03-21 Galaxy Biotech Llc Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5
CA3071922A1 (en) * 2017-08-04 2019-02-07 The Governing Council Of The University Of Toronto Nanoparticle platform for antibody and vaccine delivery
KR102348838B1 (ko) * 2019-03-07 2022-01-11 경북대학교 산학협력단 트레일 트라이머와 암표적 펩타이드를 멀티디스플레이하는 페리틴 나노케이지 및 이의 항암제로서의 용도
CA3136730A1 (en) * 2019-04-25 2020-10-29 The Regents Of The University Of California Self-assembling protein nanocage decorated with antibodies (sapna) and parts thereof

Also Published As

Publication number Publication date
MX2023006148A (es) 2023-08-07
JP2023550191A (ja) 2023-11-30
US20240182544A1 (en) 2024-06-06
CA3202378A1 (en) 2022-06-02
CN116917339A (zh) 2023-10-20
AU2021386892A9 (en) 2024-08-08
EP4251654A1 (en) 2023-10-04
WO2022109743A1 (en) 2022-06-02
AU2021386892A1 (en) 2023-06-22
EP4251654A4 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
KR102473964B1 (ko) T 세포 수용체
KR102434073B1 (ko) Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
JP2022543070A (ja) 多価及び多重特異性ナノ粒子プラットフォーム及び方法
KR20230136166A (ko) 멀타바디 구축물, 조성물, 및 방법
US11859001B2 (en) IL12RB1-Binding molecules and methods of use
CN113728005A (zh) Cd3特异性结合分子
KR20230083316A (ko) Sars-cov-2를 표적화하는 폴리펩티드, 및 관련 조성물 및 방법
US20230357414A1 (en) Il12rb2 binding molecules and methods of use
US20250171548A1 (en) IL27RAlpha BINDING MOLECULES AND METHODS OF USE
US20240182544A1 (en) Polypeptides targeting dr4 and/or dr5 and related compositions and methods
JP2023546269A (ja) T細胞を増殖させるための二重特異性コンストラクトおよび関連する方法
US20230279125A1 (en) Il28ra binding molecules and methods of use
RU2859397C2 (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ IL27Rα, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20250002564A1 (en) Modified multabody constructs, compositions, and methods
JP2024537398A (ja) SARS-CoV-2を標的とする改変されたMultabody構築物、組成物、及び方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230621

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20230628

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241125

Comment text: Request for Examination of Application